Onconetix, Inc. Hits New 52-Week Low at $2.45 Amid Major Decline

Onconetix, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 2.45 on September 22, 2025. This significant decline highlights the company's challenging performance over the past year, with a staggering 53.12% drop compared to the S&P 500's gain of 16.64%.
The company's market capitalization stands at approximately USD 4 million, reflecting its microcap status. Financial metrics indicate a price-to-book ratio of 0.65, suggesting that the stock is trading below its book value. Additionally, Onconetix has a debt-to-equity ratio of 1.33, which may raise concerns regarding its financial leverage. The company has not declared any dividends, maintaining a yield of 0.00%.

With a return on equity reported at an extreme negative figure, Onconetix's financial health appears to be under scrutiny. As the stock continues to navigate these turbulent waters, its recent performance underscores the volatility often seen in the microcap segment of the market.